Kati Förster

Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

J. Beyer-Westendorf, S. Werth, N. Weiss, 2014, Blood.

Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry

J. Beyer-Westendorf, N. Weiss, Vera Gelbricht, 2015, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

Drug Persistence with Rivaroxaban Therapy in Atrial Fibrillation Patients Results from the Dresden NOAC registry

J. Beyer-Westendorf, N. Weiss, Vera Gelbricht, 2014 .

Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.

J. Beyer-Westendorf, S. Werth, E. Kuhlisch, 2014, European heart journal.

Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation

J. Beyer-Westendorf, S. Werth, N. Weiss, 2015, Thrombosis and Haemostasis.

Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry.

J. Beyer-Westendorf, S. Werth, E. Kuhlisch, 2014, British journal of clinical pharmacology.

Pattern and Management Of Bleeding Complications With Novel Oral Anticoagulants – Results Of The Prospective Dresden Noac Registry (NCT01588119)

J. Beyer-Westendorf, S. Werth, Vera Gelbricht, 2013 .